Author: acn

NEW YORK, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) - TruMerit President and CEO Peter Preziosi has been elected President of the Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO.CoNGO | TruMeritConference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO and TruMeritCoNGO is an international non-governmental organization founded in 1948 that relates to the United Nations through its General Consultative Status granted by the United Nations Economic and Social Council (ECOSOC). It has 525 member organizations from around the world and 106 associate members.Dr. Preziosi was elected to serve for the 2025-29 term this week at the 28th CoNGO General Assembly, which took place in New York with the virtual participation of organizations from around the world. He succeeds the Rev. Dr. Liberato C. Bautista, the main representative to the UN for the General Board of Church and Society of The United Methodist Church, who has served as CoNGO's President since 2017 and also held the post from 2007 to 2011.TruMerit has been a member of CoNGO since 2018 and is active in the organization's affairs, having served as the organization's Secretary to the CoNGO Board and as chair of its Membership Committee.Dr. Preziosi is the first Registered Nurse to serve as CoNGO President. He is a nonprofit executive who since early 2023 has led TruMerit, formerly known as CGFNS International, a health workforce development organization committed to advancing the ethical mobility and professional growth of health workers worldwide. Previously, he was employed by the World Health Organization to help establish its technology-driven global learning center, the WHO Academy.Dr. Bautista, the former President of CoNGO, extended his warm congratulations to Dr. Preziosi on his election. "His experience at TruMerit and at WHO, coupled with his profound dedication to multilateralism and his engagement with civil society, provide a basis for optimism regarding CoNGO's future. In an era where the voice and influence of civil society are of paramount importance in shaping a shared future that upholds human dignity and rights, as well as planetary sustainability, Dr. Preziosi's leadership is expected to enhance CoNGO's role as a pivotal supporter and advocate for democratic and equitable participation within the United Nations and beyond," he stated."CoNGO has long been a vital convener of NGOs, a bridge between civil society and an advocate for their engagement at the United Nations, as well as a steadfast champion of inclusive multilateralism - a concept that, unfortunately, is increasingly under attack," said Preziosi."In response, let us assert civil society participation at the United Nations not as a plea, but as a principle - one that is essential to legitimate, effective, and ethical multilateralism, and thereby is critical to the attainment of the Sustainable Development Goals and adherence to the rule of law," he said.About CoNGO (Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations)The Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations (CoNGO) is an independent, international membership association founded in 1948, the year of the Universal Declaration of Human Rights. As a non-governmental organization (NGO) in general consultative status with the UN Economic and Social Council, our work relates to the entire United Nations System: the Secretariat, Agencies, Treaty Bodies, Regional Commissions, Institutes, Summits and World Conferences.CoNGO wholeheartedly endorses the goals and values enshrined in the United Nations Charter and is a strong advocate for multilateralism to resolve global political, environmental, health, and other threats. Close to 30 CoNGO Substantive Committees (called NGO Committees) related to CoNGO in New York, Geneva, Vienna, and regions worldwide demonstrate our commitment to supporting the mission of the United Nations, systemwide. CoNGO has a membership of diverse NGOs working in consultation with the United Nations, in collaboration with each other, and in cooperation with other like-minded stakeholders. ngocongo.orgAbout TruMeritTruMerit is a worldwide leader in healthcare workforce development. Formerly known as CGFNS International, the organization has a nearly 50-year history supporting the career mobility of nurses and other healthcare workers - and those who license and hire them - by validating their education, skills, and experience as they seek authorization to practice in the United States and other countries. As TruMerit, this mission has been expanded to building workforce capacity that meets the needs of people in a rapidly evolving global health landscape. Through its Global Health Workforce Development Institute, the organization is advancing evidence-based research, thought leadership, and advocacy in support of healthcare workforce development solutions, including globally recognized practice standards and certifications that will enhance career pathways for healthcare workers. www.trumerit.orgContact InformationDavid St. Johndstjohn@trumerit.orgSOURCE: TruMerit Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Auckland, New Zealand, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) - At the inaugural European Union – New Zealand Business Summit, Decent Cybersecurity represented Europe's growing strength in digital and defence technologies. The company's Founder and CEO, Matej Michalko, joined industry leaders to discuss innovation partnerships, cybersecurity resilience, and post-quantum readiness across trans-Pacific markets. The event gathered over 400 participants from business, technology, and research communities, underscoring a shared commitment to building secure and sustainable digital infrastructure between Europe and New Zealand.Hosted by Hon Todd McClay, New Zealand's Minister for Trade & Investment, in partnership with Team Europe (the Ambassadors of the EU and its Member States), the Summit celebrated the strong growth of trans-Pacific cooperation. Since the EU–NZ Free Trade Agreement entered into force in 2024, two-way trade has already risen by NZ $2 billion, reaching NZ $21.6 billion in 2025.The event was officially opened by Prime Minister Christopher Luxon, who described the EU as "an innovation partner" and emphasised the shared values and strategic alignment between Europe and New Zealand in advancing trade, defence, and technology.A Platform for Global Partnerships and Digital InnovationCommissioner Šefcovic, a native of Slovakia, delivered a keynote address outlining Europe's vision for resilient supply chains, strategic autonomy, and secure digital transition. Later in the day, the "Quickfire with Central and Eastern Europe" session showcased innovation leaders from across the region.Representing European Union and its member country Slovakia, Matej Michalko presented on the country's growing role in post-quantum cybersecurity, AI for defence systems, and trusted blockchain infrastructure — areas where Decent Cybersecurity is establishing Europe-wide leadership."It was an honour to represent European Union and Slovakia alongside Commissioner Šefcovic and to demonstrate how our country is contributing to Europe's digital and defence sovereignty," said Matej Michalko, CEO of Decent Cybersecurity. "The EU–New Zealand partnership opens new doors for innovation, technology exchange, and secure infrastructure development that transcend continents."Shared Vision for Innovation and SecurityThe Summit agenda featured strategic panels on clean tech, AI, bioeconomy, and aerospace & defence, with global leaders from Airbus, Rocket Lab, OHB, and Maersk. It culminated with a joint address by Commissioner Šefcovic and Minister McClay, setting out a shared vision for deeper economic and technological integration between Europe and New Zealand — an effort strongly endorsed by Prime Minister Luxon in his opening remarks.For Decent Cybersecurity, participation in this summit reinforces its mission to connect European post-quantum, blockchain and AI-driven innovation with global partners in the Asia-Pacific region — bridging defence, technology, and critical-infrastructure ecosystems.About Decent CybersecurityDecent Cybersecurity s. r. o. is a European deep-tech company developing post-quantum and blockchain-based cybersecurity solutions for defence and critical infrastructure. Certified by TÜV SÜD (ISO 9001 and ISO 27001) and holding NATO, EU, and national SECRET-level security clearances, the company is a member of European Defence Fund (EDF) projects and a founding member of the Critical Infrastructure Association of Slovak Republic (Asociácia kritickej infraštruktúry SR, AKI SR).Media contactBrand: Decent CybersecurityContact: Media teamWebsite: https://decentcybersecurity.eu Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world's first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC).MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10.The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China.If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon's ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon's product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector.On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.About AD IndicationMG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry2. Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) – Esperanza Fintech (Hong Kong) Limited (“Esperanza” or the “Group”) today hosted the “Conference: Implementation of Tokenized Economy by Esperanza” (“Conference”). It is an opportune moment as the Hong Kong SAR Government vows in her 2025 Policy Address to support the development of tokenized gold investment products. The Conference brought together industry leaders and partners to map out a strategic blueprint to implement tokenized economy, including the compliant roadmap for tokenized gold in Hong Kong and the unlimited potential of tokenized investments, an application for tokenized gold, in driving economic growth in the Asia-Pacific region. The Conference was attended by nearly a hundred investors and professionals.The Conference kicked off with a vision speech delivered by Mr. Ronald Leung, solicitor, Founder and Group CEO of Esperanza. Mr. Leung pointed out that the Asia-Pacific region has long relied on Western settlement systems and Western-dominated interest rate policies. The tokenized economy, powered by tokenized gold, offers an alternative capital solution to drive regional economic development and the continuous internationalization of the financial and capital markets of the Chinese Mainland and Hong Kong . He emphasized that the support for development of tokenized gold in Hong Kong’s 2025 Policy Address is a highly strategic policy direction. Capitalizing on her status and resources as an international financial center, Hong Kong possesses unparalleled edge in developing an ecosystem powered by tokenized gold in facilitating cross-border trades in the Asia-Pacific region. Furthermore, tokenized gold could be integrated with Central Bank-led digital Renminbi (RMB) in the future to contribute to the internationalization of RMB. He pointed out that the Group has completed registration with the Hong Kong Customs as an issuer of precious asset-backed instrument. The Group has also undergone a small-scale, non-public proof-of-concept (POC) testing in multiple Asia Pacific markets, including Southeast Asia, Australia, Japan, South Korea, and currently has significant verified “Know Your Customer (KYC)” POC users. Although Esperanza's tokenized gold is designed based on the legal framework for precious asset-backed instrument registered with Hong Kong Customs, to ensure overall regulatory stability in Hong Kong, it is anticipated that Esperanza will open its tokenized gold offerings to the Hong Kong public only after addressing the concerns of other regulatory bodies and when a clear regulatory framework is fully implemented in the city. The Group will also align with governments of various economies on operational fronts via strategic partners.Mr. Leung continued to point out, "Tokenized gold is a key milestone for Hong Kong's financial future. Esperanza has already signed an agreement with Hatcher Group Limited (8365.HK) regarding the development of tokenized gold before the Policy Address was released. Immediately following the release, our team has conducted a productive and in-depth communication with the Chief Executive's Policy Unit, while ensuring our technology platform and infrastructure are in place and ready for action. Currently, we are maintaining active dialogues with regulators, with the core principle of achieving ‘controllable innovation’ that adheres to existing regulatory framework as well as the work agenda of the Chief Executive’s Policy Unit. We firmly believe that Esperanza, armed with first-mover advantages in technology and its business model, and in collaboration with various sectors, will be able to transform tokenized gold into a powerful engine in driving economic autonomy in the Asia-Pacific region."The conference had two thematic sharing sessions. The first had Mr. Roy Lui, Managing Director of ESPE Gold Solutions, sharing the compliant implementation of tokenized gold in Hong Kong. Mr. Lui shared that the Group’s proposed solution – “ESPE Gold” (“ESPG”) – is legally categorized as a “precious asset-backed instrument” instead of a virtual asset or a stablecoin, nor a collective investment scheme. Esperanza purchases physical gold bars adhering to London Bullion Market Association (LBMA) standards, stores them in licensed gold vaults and issues 100,000 ESPG, i.e. digital gold certificates, for each kilogram of gold bar. These digital gold certificates, each representing a complete instalment payment, are recorded on blockchain networks. Upon completion of 100,000 instalments, i.e. holding 100,000 ESPG, clients can redeem physical gold bars from Esperanza. Clients can make instalment payments any time and sell ESPG back to Esperanza, enjoying much higher flexibility than traditional gold redemption clubs. Mr. Lui emphasized that, although ESPG gives users experiences similar to that of stablecoins, the business model is actually more akin to traditional gold dealers earning bid-ask spread. He also spoke on the diverse application scenarios of ESPG besides as a convenient way to purchase physical gold. ESPG is poised to develop into a cross-border settlement means for commerce across Asia economies, with future potential to power a gold-backed interest rate system through collateralized lending of ESPG.In the second sharing session, Mr. Tony Chang, Executive Director of ESPE Capital Solutions, talked about the Group’s blueprint for tokenized investments as a core use case for tokenized gold. Mr. Chang said tokenized investments have not seen significant breakthrough due to the lack of product designs that are attractive to investors and that liquidity is highly concentrated within professional investors. Tokenized investments need to deliver both “attractive growth potential” and “security in exit channels” in order for investors to make meaningful consideration for adoption. Such example includes a short-term revenue sharing arrangement with foreseeable potential for revenue improvement. He added that Esperanza has obtained the Asset Management licence from the Securities and Futures Commission (SFC) of Hong Kong and its application for tokenized business is currently under review, with the legal, tax, and trading infrastructures ready. Currently, the Group’s tokenized investment pipelines include concert revenue of Southeast Asian and Korean artists, movie box office receipts and revenue of hotels and shopping malls.In addition to the thematic sharing sessions, the conference also featured a panel discussion comprising Mr. Jeremy Teo from Singapore, Co-founder and Board Director of Esperanza, Mr. Ronald Leung and Mr. Tony Chang. The discussion centers on the development potential of tokenized gold and tokenized investments across various Asia-Pacific economies, particularly the opportunities in bringing Southeast Asian projects to Hong Kong for capital raising via security token offerings (STOs). These opportunities illustrate the advantages for Hong Kong in developing tokenized gold with the support of the Hong Kong SAR Government.The conference marked an important step made by Esperanza in promoting the development of tokenized economy in Hong Kong and across Asia. Looking ahead, the Group will continue to provide innovative fintech solutions to support Hong Kong in strengthening her position as an international financial center, as well as helping foster greater economic autonomy and financial innovation in the Asia-Pacific region.Photo captionsPhoto 1: (From left to right) Mr. Tony Chang, Executive Director of ESPE Capital Solutions, and Mr. Ronald Leung, Founder and Group CEO of Esperanza, and Mr. Roy Lui, Managing Director of ESPE Gold Solutions, at the conference.Photo 2: (From left to right) Mr. Jeremy Teo, Co-founder and Board Director of Esperanza, Mr. Ronald Leung, Founder and Group CEO of Esperanza, and Mr. Tony Chang, Executive Director of ESPE Capital Solutions, after the panel discussion session.About Esperanza Fintech (Hong Kong) Limited (Esperanza)Esperanza is co-founded by the next generation of professionals from Hong Kong and Singapore with the mission to reform Asia’s economies through fintech. Esperanza is building the world’s first digital economy powered by a compliant tokenized gold infrastructure and its applications in finance. Esperanza aspires to reconnect Asia’s economies and integrate with their respective Central Bank Digital Currencies (CBDCs) to build autonomy against reliance on Western settlement systems and interest rate policies.Esperanza operates on a low-profile, highly efficient, and decisive business model. Since commencement in 2025, Esperanza has secured the registration as a Precious Metals and Stones Dealer (DPMS) with Hong Kong Customers and the Trust or Company Service Provider (TCSP) licence for the operations and custody of tokenized gold, and the Asset Management licence with the Securities and Futures Commission (SFC) of Hong Kong for the development of tokenized investments.In August 2025, Esperanza entered into a partnership agreement with Hatcher Group (8365.HK) relating to tokenized gold and tokenized investments. In September 2025, Hong Kong government has included the development of tokenized gold into its 2025 Policy Address.Esperanza's tokenized gold and tokenized investments continue to adhere to Hong Kong's Anti-Money Laundering (AML) requirements and common reporting standard for counter-tax evasion measures. Fintech solutions have enabled Esperanza to significantly reduce financing and operational costs, connecting products directly with end users. Esperanza’s tokenized finance system will fully support the globalization of national economy and is committed to becoming an alternative solution for international trades and settlements.To find out more, please visit the Esperanza website: espetopia.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2025年10月30日 - (亚太商訊) - 康哲药业控股有限公司（"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业2025年4月22日发布的公告）连同其附属公司拥有共同开发权（除特应性皮炎（AD）外）和独家商业化权利的1类新药抗IL-4Rα MG-K10人源化单抗注射液（"MG-K10"或"产品"）中国上市许可申请（"NDA"）于2025年10月30日获得中国国家药品监督管理局（NMPA）受理。产品拟用于治疗外用药控制不佳或不适用外用药治疗的成人中重度特应性皮炎。MG-K10（通用名为柯美奇拜单抗注射液）是一种创新的长效抗IL-4Rα人源化单抗，能同时阻断关键2型炎症因子IL-4和IL-13的信号传导。凭借更长的半衰期，产品可实现4周一次的给药频率（已上市抗IL-4Rα药物均为2周一次给药频率），提升患者依从性，并有望成为全球首个上市的长效抗IL-4Rα单抗，具有成为同类最优（Best-in-Class）的潜力。MG-K10已在成人中重度AD的一项随机、双盲、安慰剂对照III期临床研究取得阳性结果，达到方案设计的临床试验主要研究终点，且MG-K10治疗52周时，研究者整体评估（IGA）评分达到0或1分，且较基线改善≥2分的受试者比例为 76.6%；达到湿疹面积及严重程度指数评分较基线至少改善75%（EASI 75）的受试者比例为94.3%；达到湿疹面积及严重程度指数评分较基线至少改善90%（EASI 90）的受试者比例为79.1%。安全性方面，治疗期不良事件（TEAE）大多数为1-2级，未发生特别关注不良事件（AESI），未发生导致死亡的不良事件。同靶点药物常见的不良反应（结膜炎、注射部位反应等）MG-K10发生率较低。产品有潜力用于治疗其他2型炎症性疾病，如哮喘、结节性痒疹、季节性过敏性鼻炎、慢性阻塞性肺疾病、慢性自发性荨麻疹、慢性鼻窦炎伴鼻息肉及嗜酸性粒细胞性食管炎等。其中，哮喘、结节性痒疹和季节性过敏性鼻炎均已进入中国III期临床试验阶段。若该产品获批上市，将为超1,450万中重度AD患者[1]带来新的有效且安全的系统治疗选择。同时，MG-K10将与德镁医药的磷酸芦可替尼乳膏（轻中度AD）、口服小分子TYK2抑制剂CMS-D001（中重度AD），及皮肤学级护肤品禾零舒缓系列形成协同效应，构建覆盖注射、口服与外用等多种给药途径，兼顾"治疗+护理"多重需求的AD综合解决方案，惠及广大特应性皮炎患者；并将进一步丰富德镁医药皮肤治疗领域的产品矩阵，巩固其在皮肤健康领域的领先地位。于2025年1月24日，康哲药业通过其附属公司与湖南麦济生物技术股份有限公司及其附属公司就MG-K10签订合作协议（"协议"）。根据该协议及补充约定，康哲药业获得了产品在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及新加坡的共同开发权（除AD外）及独家商业化权利；其中旗下德镁医药通过其附属公司获得该产品在皮肤科适应症领域于中国大陆的共同开发权（除AD外）及独家商业化权利。关于AD适应症MG-K10的首发适应症AD是一种伴有剧烈瘙痒的慢性炎症性皮肤病，是全球疾病负担最高的非致命性皮肤病，同时也是我国患病率较高、疾病负担较重的慢性疾病。据估算，2024年中国特应性皮炎患者超过5,400万人，基于SCORAD评分，中重度特应性皮炎的占比为27%，即超过1,450万患者[1]。由于传统AD系统治疗药物疗效及安全性等方面的不足，在临床中，中重度AD患者启动系统治疗往往较晚、依从性不佳、总体控制率较低，临床上仍存在大量未被满足的治疗需求[2]。MG-K10给药间隔更长，每4周给药一次，有望提升患者依从性，给中重度AD患者带来新的有效且安全的系统治疗选择。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1. 灼识咨询.《全球及中国皮肤科治疗与护理行业研究报告》2. 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 中国中重度特应性皮炎诊疗临床路径专家共识（2023版）[J] . 中华皮肤科杂志, 2023, 56(11) : 1000-1007. DOI: 10.35541/cjd.20230247.康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol “NBP”), to secure an exclusive license to develop, manufacture and commercialize VIS-101, in Greater China, Singapore, South Korea and certain Southeast Asian countries.This collaboration marks Everest’s strategic expansion into ophthalmology, a high-potential “blue-ocean” therapeutic area, further enriching its late-stage product pipeline and strengthening synergies across its core therapeutic portfolio.Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and reimburse up to RMB24.0 million for prior expenses; and pay up to US$89.0 million (equivalent to approximately RMB632.0 million) in potential milestones; plus tied royalties on net sales.“We are pleased to collaborate with Visara. This partnership brings a highly differentiated and commercially attractive asset to Everest’s late-stage product pipeline and marks our entry into ophthalmology, a competitively attractive therapeutic area with significant unmet medical needs,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Leveraging Everest’s clinical development and commercialization expertise, we look forward to advancing VIS-101, a potential best-in-class bifunctional antibody, towards commercialization in China and across Asia.”VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2 that is more potent and could potentially provide more durable treatment benefits than existing treatments for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 has completed initial safety and dose-escalation studies in both the United State of America and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.“VIS-101 is anticipated to be second-in-class with best-in-class potential, based on bioengineered, superior target neutralizing capabilities.” said Dr. Emmett T. Cunningham, Jr, Co-Founder and Executive Chairman of Visara.Globally, the market size for anti-VEGF ophthalmic drugs reached approximately USD 23 billion in 2024 and is projected to exceed USD 40 billion by 2030. In China alone, the prevalent patient population of AMD and DME exceeds 15 million, with around 600,000 new cases each year, yet only about 500,000 patients currently receive treatment. This indicates vast market potential.Visara is a subsidiary of NovaBridge Biosciences (Nasdaq: NBP), of which Everest Medicines is currently the largest shareholder. “Licensing out Greater China, South Korea and Southeast Asia rights to Everest Medicines is an important step toward streamlining global commercial rights and creating synergy in global clinical development,” said Dr. Sean Fu, Chief Executive Officer of NovaBridge Biosciences. “We are excited to work with Everest Medicines team as a strategic partner."Under its “dual-engine” strategy, Everest Medicines has established a commercialization platform anchored by two blockbuster products targeting high-potential markets and powered by the in-house in vivo CAR-T and mRNA therapeutic cancer vaccine platforms. The Company will continue to focus on key therapeutic areas and new growth markets, with ophthalmology as the next growth driver to strengthen synergy across its core portfolio.Everest’s core product pipeline in rental diseases, infectious diseases, and autoimmune disorders has entered a critical growth stage. NEFECON® and XERAVA® have established sustainable commercial cash flow generation, while VELSIPITY® (etrasimod) is expected to become the company’s next blockbuster product. Everest continues to enhance its innovation capability and long-term competitiveness by leveraging its industry-leading mRNA therapeutic cancer vaccine platform and mRNA in vivo CAR-T platform.At a recent corporate strategy meeting, Everest Medicines announced plans to in-license more than three high-potential assets within the next 6–12 months, with an aggregate domestic peak sales potential exceeding RMB10 billion. Combined with its existing portfolio, Everest Medicines expects its total domestic peak sales potential to surpass RMB20 billion. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亚太商訊) - 10月30日，云顶新耀宣布已与Visara签订协议，获得独家许可，在大中华区、新加坡、韩国及若干东南亚国家进行临床开发、生产和商业化VIS-101。该合作标志着云顶新耀正式进军眼科这一高潜力蓝海领域，丰富了公司的后期产品管线，进一步拓展其核心治疗领域布局。根据指定独家许可，云顶新耀将支付700万美元（相当于约人民币4,970万元）的预付款，及不超过人民币2,400万元的自付费用报销；最高不超过8,900万美元（相当于约人民币6.32亿元）的潜在开发及销售里程碑款项；以及按净销售额的潜在特许权使用费。云顶新耀首席执行官罗永庆先生表示："我们非常高兴与Visara建立合作伙伴关系，此次战略合作引入的创新药物VIS-101兼具高度差异化与商业潜力，进一步丰富了公司的后期产品管线，并将业务拓展至眼科这一临床需求尚未充分满足且具有创新机会的蓝海治疗领域，为公司发展注入新的增长动能。未来，我们将依托公司卓越的临床开发能力和商业化平台，高效推进VIS-101这一潜在同类最佳的双功能生物制剂在中国及亚洲地区的临床开发与商业化进程，尽快为患者提供这一创新治疗选择。"VIS-101是一款新型双功能生物制剂，针对VEGF-A与ANG-2，其疗效较第一代治疗更为显著，可有望为湿性年龄相关性黄斑部病变（wet AMD）、糖尿病性黄斑部水肿（DME）及视网膜静脉阻塞（RVO）患者提供更持久的治疗效益。VIS-101已于美国及中国完成初步安全性与剂量递增研究，目前正于中国进行随机分组的剂量范围II期临床试验，预计将于2026年具备进入III期临床试验的条件。Visara联合创始人兼执行主席Cunningham博士表示："VIS-101有望成为该类别中第二款上市的药物，并具备同类最佳（best-in-class）的潜力。这源于其在生物工程上的优异设计，使其具备更强的靶点中和能力。"目前，抗VEGF（血管内皮生长因子）疗法是眼底疾病的主要治疗手段，通过抑制眼内异常新生血管的生成与渗漏，从而改善视功能。2024年全球抗VEGF眼科药物市场规模已达约230亿美元，预计到2030年将超过400亿美元。眼科药物市场空间广阔，仅在中国，wet AMD和DME的现有及新增患者人数已超过1,500万，每年新增约60万例，而目前接受抗VEGF治疗的患者人数仅约50万，存在巨大的未被满足的临床需求。Visara为新桥生物（前称为I-Mab，纳斯达克股票代码：NBP）的附属公司，云顶新耀目前是新桥生物的第一大股东。新桥生物首席执行官傅希涌博士表示："此次将VIS-101大中华区、韩国及东南亚地区的权益授权给云顶新耀，是我们在优化全球商业布局、推动全球临床开发协同方面迈出的重要一步。我们期待与云顶新耀共同推进该产品在亚洲地区的战略协作，为更多患者带来创新治疗选择。"此次合作是云顶新耀在"双轮驱动"战略指导下的又一关键落子。公司正在构建以多个大单品商业化平台为基石、以自体生成CAR-T平台与mRNA肿瘤治疗性疫苗平台的自主研发与临床转化为引擎的价值体系。未来，公司将持续聚焦优势治疗领域，引进高潜产品，进一步强化核心产品组合的协同效应。目前，云顶新耀在肾科、感染及自身免疫性疾病等核心治疗领域的产品管线已进入关键收获期。耐赋康(R)与依嘉(R)已形成可持续的商业化造血能力，维适平(R)（艾曲莫德）有望成为下一个确定性大单品。在自主研发方面，公司依托领先的mRNA肿瘤治疗性疫苗平台与自体生成CAR-T平台为核心，持续夯实自研技术壁垒。在近期的发展战略交流会上，公司进一步明确未来6-12个月计划引进3个以上的重磅产品，预计引进产品的潜在国内销售峰值将超过人民币100亿元，叠加现有产品矩阵，整体国内销售峰值有望突破人民币200亿元。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亚太商訊) - 专注于中国健康饮食行业的透云生物科技集团有限公司（「透云生物」，连同其附属公司统称「集团」；股份代号：1332.HK）欣然宣布，集团旗下全资子公司山西透云生物科技有限公司近日与中国健康产品领域知名渠道商多家核心伙伴，包括深圳楼宇间供应链科技股份有限公司、河南国字头营销管理有限公司及北京合万家生物科技有限公司，组成之销售联合体正式签署战略合作协议。根据战略合作协议，2026年至2028年底，上述销售联合体将向透云生物采购总金额不少于人民币10亿元之莱茵衣藻系列产品。此标志性合作不仅为集团莱茵衣藻业务奠定量级放大之商业基础，亦宣示相关产品线已由区域性试点阶段迈向全国化、结构化铺排与放量，进一步夯实透云生物于中国健康膳食、功能营养与绿色食品原料赛道的产业领先地位。本次采购协议的正式落地，标志着透云生物的莱茵衣藻及微藻产品已由研发验证与先导试用阶段，全面迈入可规模交付的商业化新阶段 — 即具备工业化、标准化、可持续、可追溯之稳定供应能力。是次协议属量级采购安排，亦即对产能、品质一致性、合规体系、供应链韧性及交付节奏的全方位验证。对集团而言，这不仅是一笔订单，更是一个产业拐点 — 莱茵衣藻正由「创新食材」走向「行业标配」。此里程碑进一步巩固集团「新一代绿色蛋白与功能营养供应商」之市场定位。透云生物不再只是提供单一原料，而是输出一整套可复制的营养解决方案 — 涵盖低GI配方、高蛋白/全胺基酸谱设计、富微量元素强化方案、以及针对不同消费人群（控糖人群、体重管理人群、三高风险人群、银发族等）的功能型膳食应用模组。集团预期，是次合作将在放量、场景扩展与C端渗透三个层面产生牵引效应：i) 推动其莱茵衣藻业务由区域性试点销售走向全国性铺排，实现生产端与销售端的同步扩容与规模经济；ii) 加速微藻原料进入更多日常高频品类，包括健康主食、便利即食、功能代餐、餐饮定制菜单、营养加强型小食等，使其从「创新亮点」变为「常规标配」；及iii) 以B端（餐饮、渠道、大健康企业）作为推进枢纽，带动消费端对藻基营养的认知与接受度，构建「微藻＝健康」的普遍心智，为品牌后续直接面向消费者的零售型产品铺垫基础。集团相信，随着是次协议所对应的采购需求逐步兑现，透云生物将能为健康主食、控糖控脂膳食方案、功能型即食／速食产品、代餐营养品等快速增长的细分市场，提供可持续、可标准化、可长期追溯的高规格原料底座，从而在中国「健康膳食产业升级」的进程中占据更具战略性的供应端主导位置。透云生物董事会主席兼执行董事王亮先生表示：「当前，消费者对健康饮食的理解已不再局限于传统的『少油少盐』，而是进一步聚焦于『高营养、可持续、具功能诉求』。本次签订人民币10亿元的战略采购协议，乃市场对透云生物于工业化量产能力、品质一致性、标准化交付能力以及研发迭代速度的系统性肯定。展望未来，集团将继续强化供应链韧性，在保障食品安全与品质稳定的前提下，有序扩大产能，进一步完善原料端、配方端、应用端的全链条能力。集团会持续输出标准化、模组化、低GI及富微量元素的整体营养解决方案，协助合作伙伴升级其核心产品线，并推动莱茵衣藻走入更广泛的民生场景，最终让高营养、低碳足迹的绿色食品真正普及到千家万户。透云生物的战略定位，是成为中国健康主食与功能餐饮领域的养生原料标准制定者与长期供应者，并以中国为起点，逐步走向全球。」关于透云生物科技集团有限公司透云生物科技集团有限公司（股份代号：1332.HK）主要从事莱茵衣藻产品业务、包装产品设计、研发、生产及销售业务，同时亦为向中国快速消费品提供产品包装上的二维码以及商务智慧资讯技术解决方案的市场领导者。集团扎根传统包装业务超过三十载，在香港以及广东多地设有办公室及制造车间，目前为众多世界知名品牌提供专业包装设计及制造服务，拥有长期稳定的客户群。自2020年起，集团多元化发展业务范围至莱茵衣藻、微藻产品业务，并与山西省长治市潞城区人民政府合作建设全球首座莱茵衣藻工厂，以展开莱茵衣藻工业化量产。如欲查询更多资料，请浏览集团网站：https://touyunbiotech.com.hk/zh-hant/ Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Japan – October 30, 2025 - (ACN Newswire via SeaPRwire.com) - The Northeast Asia Video Summit 2025, hosted by the Asia Video Industry Association (AVIA), brought together leading media executives, content creators, and technology innovators to explore the future of video in Japan and Korea. Held in Tokyo, the summit showcased transformative strategies in global content production, streaming monetization, and cross-border collaboration.A central theme of the summit was the global ascent of Japanese and Korean content. In a compelling keynote, Katsuaki Setoguchi, Executive Officer at TBS Holdings and President and CEO of THE SEVEN Inc., emphasized that Japan’s ambition to go global is rooted not in profit, but in cultural promotion. “Storytelling is our foundation,” Setoguchi said, highlighting the success of Alice in Borderland and upcoming co-productions with U-Next. He outlined a formula for global success: strategic IP selection, elevated production budgets, and partnerships with platforms like Netflix and Amazon to reach a global audience. Setoguchi also stressed the importance of long-term regional collaboration, particularly in Southeast Asia, citing their strategic alliance with Vietnam TV.Yu Sasamoto, CEO of DAZN Japan and APAC Business Development, shared insights into Japan’s evolving sports streaming landscape. With partnerships like Docomo and Meta, DAZN is redefining how fans engage with live sports. Sasamoto revealed that DAZN is set to triple its subscriber base in Japan and is leveraging social media to convert engagement into subscriptions. Sasamoto also shared his ambitions to expand Japanese sports globally by building an ecosystem that blends content, technology, and partnerships to scale across Asia.Streaming monetization was another hot topic. Joshua Sunghyun Cho, CBO of TVING, detailed the platform’s innovative ad strategies, including impression-guaranteed products and interactive formats like “Watch Together.” Partnering with Moloco, TVING doubled its ad revenue from KBO baseball broadcasts and is now targeting contextual and shopping ads. “Streaming is no longer just premium branding—it’s performance-driven,” Cho said. Nick Chuah, Managing Director APAC at INVIDI, added that addressable advertising is poised to reshape Japan’s TV ad market, with data-driven campaigns delivering measurable ROI and unlocking new value for brands.Executives from Dentsu, FAST Corporation, and Integral Ad Science also echoed the need for collaboration, standardization, and advocacy to accelerate CTV adoption in Japan. With new smart TVs and platforms like TVer and ABEMA entering the programmatic space, the market is poised for rapid growth.The summit also addressed the future of anime as a global cultural force. Yuichiro Saito, CEO of Studio CHIZU, and Hideki Henry Goto, President of OKUTAGON LLC, discussed anime’s expanding international footprint. With over half of revenue now coming from global markets, speakers called for new business models, international co-productions, and talent development to sustain growth, with Saito advocating for creative integrity and global collaboration.In the closing keynote, executives from Warner Bros. Discovery, SKY Perfect JSAT, and A+E Global Media debated the future of pay TV and streaming economics in Japan. While acknowledging the slow decline of linear TV, they emphasized the enduring value of local partnerships and bundling strategies. Japan’s rich history and vibrant culture continue to produce compelling stories, presenting vast opportunities for international partnerships to bring this content to global audiences. The speakers agreed that creative distribution models and co-productions will be key to unlocking Japan’s full potential on the global stage.The Northeast Asia Video Summit is proudly sponsored by Gold Sponsors Moloco and Publica by IAS, and Silver Sponsors Encompass, INVIDI and TV5MONDE.Click here for a selection of photos from the Summit.About the Asia Video Industry AssociationThe Asia Video Industry Association (AVIA) is the trade association for the video industry and ecosystem in Asia Pacific. It serves to make the video industry stronger and healthier through promoting the common interests of its members. AVIA is the interlocutor for the industry with governments across the region, leads the fight against video piracy through its Coalition Against Piracy (CAP) and provides insight into the video industry through reports and conferences aimed to support a vibrant video industry.For media enquiries and additional background information, please contact:Charmaine KwanHead of Marketing and CommunicationsEmail: charmaine@avia.org | Website: www.avia.orgLinkedIn: www.linkedin.com/company/asiavideoia |X: @AsiaVideoIA Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Placement of 20,000,000 Placement Shares at S$0.39 each has been fully taken up, raising gross proceeds of S$7.8 million.Prominent institutional funds and investors that subscribed for the Placement Shares include Lion Global Investors Limited (as investment manager for and on behalf of its clients), Asdew Acquisitions Pte Ltd, ICH Synergrowth Fund, Ginko-AGT Global Growth Fund and Mr Tan Kim Seng, among others.Supported by Singapore’s robust construction outlook of S$39 billion to S$46 billion annually from 2026 to 2029 and large-scale coastal protection initiatives of S$100 billion, the Group is well-positioned to capitalise on growth opportunities with its integrated and synergistic business model.SAC Capital Private Limited acted as the Placement Agent in relation to the Placement. Maybank Securities Pte. Ltd. acted as the Placement Agent and the Sub-Placement Agent.Singapore, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) - SGX-Catalist listed Reclaims Global Limited (“Reclaims Global” or the “Company” and together with its subsidiary, the “Group”), an eco-friendly integrated service provider within Singapore’s construction sector, is pleased to announce that the Company has successfully completed a share placement (“Placement”), comprising a total of 20,000,000 new shares issued at a price of S$0.39 per share, raising gross proceeds of S$7.8 million.With its integrated and synergistic business model within Singapore’s construction industry, the Group specialises in the customisation of excavation/demolition/building construction solutions, operating fleet management of construction vehicles and equipment as well as the recycling of construction and demolition waste.“This successful placement marks a key milestone for the Group as the macro growth momentum in Singapore’s construction industry, coupled with national investment in coastal protection initiatives, creates opportunities for Reclaims Global to deliver enhanced long-term value to our stakeholders,” said Mr. Chan Chew Leh, Executive Chairman.“Building on our established foundation and track record within the construction industry, Reclaims Global is well-positioned to pursue larger-scale projects as a trusted partner. Backed by strong sectoral tailwinds, we aim to expand our market presence and capture new business opportunities via our integrated and synergistic business model,” added Mr. Tan Kok Huat, Executive Director and Chief Executive Officer.In its latest 1H2026 results (for the financial year ended 31 July 2025) announced on 9 September 2025, Reclaims Global reported revenue growth of 14.9% to S$21.78 million (as compared to previous corresponding period) with net profit of S$2.5 million. The Company has announced an interim dividend of S$0.005 per share for 1H2026 and over the past two years, the Company has paid at least S$0.01 per share of dividends annually.About Reclaims Global Limited(SGX - NEX / Bloomberg - RGL: SP/ Reuters - RECL.SI)Listed on the Catalist of the SGX-ST in March 2019, Reclaims Global Limited is an eco-friendly integrated service provider within Singapore’s construction industry, specialising in the customisation of excavation/demolition/building construction solutions, operating fleet management of construction vehicles and equipment as well as the recycling of construction and demolition waste.The Group’s integrated and synergistic business model is organised into three main business segments as follows: (1) excavation services; (2) logistics and leasing; and (3) recycling.Since its inception in 2009, the Group has established a strong reputation and proven track record for reliable execution and timely delivery of diverse projects across the construction sector.For more information, please refer to the corporate website https://reclaims-enterprise.comIssued on behalf of Reclaims Global Limited by 8PR Asia Pte Ltd.Media & Investor Contacts:Mr. Alex TANMobile: +65 9451 5252Email: alex.tan@8prasia.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亚太商訊) - 10月27日，中国新能源汽车行业中的头部企业——赛力斯集团股份有限公司（「赛力斯」，股份代号：9927）正式启动招股，赴港上市更进一步，此次上市若顺利完成，公司有望成为港股市场首家实现「A+H」两地上市的豪华新能源车企。问界M9丰富产品矩阵 市场表现亮眼作为一家以新能源汽车为核心业务的技术科技型企业，赛力斯业务版图全面覆盖新能源汽车及核心三电等产品的研发、制造、销售及服务。公司旗下高端品牌「问界」精准聚焦豪华细分市场，凭借清晰的产品定位、出色的综合性能及豪华的属性，在行业内收获高度认可，被业内人士誉为「中国的奔驰宝马」。而从科技维度出发，问界在品牌「智慧重塑豪华」理念的推动下，展现出「豪华+科技」双轨并行的独特定位。在定义未来科技出行方面，如辅助驾驶、智能安全、智能动力等，问界又与特斯拉秉持高度一致的愿景。截至目前，问界系列车型的辅助驾驶功能累计行驶里程已突破34.5亿公里，辅助驾驶行驶里程占总里程比例40%，辅助驾驶功能成绩亮眼。与此同时，赛力斯在科技创新与前沿科技持续探索，积极布局具身智能领域，近期公司已正式宣布与火山引擎达成合作，共同推进具身智能的研发与应用创新，显示出与国际领先车企不谋而合的战略前瞻性。在科技领域的成绩与探索也使得问界品牌被业内人士誉为「中国的特斯拉」。揆诸实际，无论是问界在豪华细分市场的深耕与精准定位，还是当下辅助驾驶等科技成果的稳健落地，正是对「智慧重塑豪华」品牌理念的深度践行。这一理念精准契合用户对智能与豪华并重的核心要求，让用户无需在豪华质感与智能体验间作出取舍，既避免了在单一维度发展的局限，更让「豪华 + 科技」的双重价值真正转化为用户可感知的日常使用体验。在产品端，问界品牌已构建起覆盖问界M9、问界M8、问界M7、问界M5的完整产品矩阵，实现对高端市场的全面渗透，市场表现持续亮眼，旗下主力车型长期领跑细分市场，2024年问界M9稳居50万级高端SUV销量冠军，问界M8在2025年4月正式上市后仅24小时大定即突破3万。根据Frost & Sullivan报告，问界品牌在2024年下半年以82%的NPS净推荐值登顶新能源汽车口碑榜首，且2024年问界品牌全年总交付量达38.71万辆，同比增长268%，充分印证了其在高端新能源汽车市场的核心竞争力。问界全系列强化研发投入与技术创新 业绩增长强劲在夯实产品矩阵、巩固市场份额的同时，赛力斯持续深耕技术创新领域，以高强度研发投入筑牢发展根基。于2022年、2023年、2024年以及2025年上半年，公司研发开支分别达人民币1,313.7百万元、人民币1,696.5百万元、人民币5,585.5百万元及人民币2,929.5百万元，呈现显著增长态势。从研发费用占收入比重来看，各期分别为3.9%、4.7%、3.8%及4.7%，彰显出公司对技术创新的高度重视。领先的核心技术能力，是赛力斯的产品持续实现功能创新、获得市场成功的重要驱动力之一。公司自主打造的魔方技术平台，通过平台化造车模式，有效降低了整车开发成本，同时大幅提升开发的敏捷性和灵活性。该平台凭借全景安全、多元动力、百变空间、智慧引领四大核心优势，为用户提供了「好开、好用、超安全」的智能用车体验。同时，作为首家商业化量产增程器的自主整车企业，赛力斯持续引领新能源车增程技术的发展，将增程技术从「可用」进化到「好用」，并在油电转换率和NVH性能两项关键指针上获得国家权威认证机构的认可，其最新发布的全新一代超级增程系统油电转换效率达到3.65kWh/L，处于行业量产增程器的最高水平。此外，赛力斯始终将产品安全视为底线，围绕车辆全生命周期，构建了涵盖被动安全、主动安全等九大维度的智能安全体系。目前，公司开发了81项碰撞场景，搭载该体系的问界M9荣获C-NCAP、C-IASI国内两大测评指数双第一的优异成绩。在ESG治理与可持续发展领域中，赛力斯也取得亮眼成绩，2025年10月16日，根据国际权威指数公司明晟(MSCI) 公布最新企业ESG评级结果，赛力斯集团获得最高AAA评级，成为唯一获此评级的A股上市汽车企业，彰显赛力斯集团在构建未来出行生态中的引领力量。值得一提的是，公司通过融合创新的方式与合作伙伴共同打造了先进的智能座舱和辅助驾驶功能，并通过深度融合整车控制技术，从整车跨域协同维度持续优化辅助驾驶体验，为用户提供更加智能、便捷的驾驶感受。财务表现上，赛力斯近年业绩增长势头强劲，盈利成果显著。2023年至2024年，公司收入从人民币358亿元跃升至1451亿元，同比大幅增长305.5%；公司毛利率同步提升，从2023年的7.2%稳步增至2025年上半年的26.5%，盈利空间持续拓宽。盈利层面，公司于2024年、2025年上半年分别录得归母净利润人民币59亿元、人民币29亿元，成功实现盈利突破。根据Frost & Sullivan报告，公司是全球第四家实现盈利的新能源车企，财务健康度与行业竞争力凸显。总体而言，赛力斯凭借清晰的高端产品布局、领先的技术创新与稳健的盈利增长，已在新能源汽车赛道建立起稳固的行业地位。此次拟赴港上市，既是对其过往发展成果的认可，更将为其深化技术研发、拓展全球市场注入新动能，有望在全球汽车产业变革中持续领跑，为中国自主品牌车企高质量发展写下新的注脚。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亚太商訊) - 10月27日，中国新能源汽车行业头部企业—赛力斯（股份代号：9927）启动招股，目前招股正在进行中，即将叩开港股市场大门，有望成为首家A+H豪华新能源车企。极具竞争力的产品体系在产品层面，赛力斯凭借深厚的技术积淀与精准的市场定位，构建起极具竞争力的产品体系。其中，公司于2021年重磅发布的高端品牌「问界」，截至目前，问界品牌已成功推出问界M5、问界M7、问界M8及问界M9四款核心产品，累计服务用户已突破80万。更值得关注的是，公司旗下主力车型长期稳居细分市场头部阵营，问界M9持续领跑高端SUV赛道，稳居50万级市场销量冠军。问界M8始终稳居40万级市场榜首，成为高端用户的首选之一。问界M9凭借「双旗舰」车型的亮眼表现与强大品牌影响力，赛力斯被业界高度认可，赢得了「中国的奔驰宝马」这一重磅赞誉，彰显出公司在高端新能源汽车市场的领军地位。在定义辅助驾驶、智能安全、智能动力等未来出行领域，赛力斯与特斯拉秉持高度一致的愿景。截至目前，问界系列车型的辅助驾驶功能累计行驶里程已突破34.5亿公里，在该领域，仅特斯拉与问界稳居前两位，迭加赛力斯在具身智能与科技创新领域的持续深耕与积极探索，赛力斯被行业广泛视作「中国的特斯拉」。问界对豪华市场的深耕定位与辅助驾驶等科技成果的落地，既是 “智慧重塑豪华” 理念的深度实践，也精准匹配用户对智能与豪华兼具的需求，跳出单一维度发展局限，让 “豪华 + 科技” 价值成为用户可感知的体验。全方位的技术创新实力在技术层面，赛力斯持续推动技术创新，逐步确立行业竞争优势并打造坚实的技术壁垒。公司自主研发的魔方技术平台，是具备持续进化能力的智能平台，也是行业内首个兼容增程、纯电与混动三种新能源动力总成的平台，其模块化设计使公司能够高效、可靠地实现系列车型的快速量产。目前，赛力斯最新一代超级增程系统已实现量产，热效率高达44.8%，油电转化率达到3.65kWh/L，处于行业领先水平。魔方技术平台在用户安全方面，赛力斯以全场景安全需求为驱动，全面构建覆盖被动安全、主动安全等九大维度的安全体系，涵盖超过180项用户用车场景，开发出300余项安全功能，打造全方位的安全防护能力。此外，赛力斯还构建了端云一体化的测试平台，其自研的智能测试终端可实现测试车辆7×24小时不间断的自动化测试。通过自动化测试技术，公司构建了覆盖研发、生产、供应、销售全流程的质量自动化拦截体系，全面保障产品质量。赛力斯在 ESG 治理与可持续发展领域同样成效显著，2025 年 10 月 16 日拿下国际权威机构明晟（MSCI）最高 AAA 评级，作为 A 股上市车企中唯一获此评级的企业，其未来出行生态引领地位得以凸显。财务方面，赛力斯近年来实现跨越式增长，业绩表现尤为亮眼。2024年营业收入突破1451亿元，同比增长305.5%，实现归母净利润59亿元，成功实现历史性扭亏为盈，2025年上半年，公司延续盈利向好态势，实现净利润29亿元，展现出强劲增长势头。赛力斯以产品力、技术壁垒与安全体系筑牢发展根基，凭亮眼财务数据印证强劲实力。若此次赴港上市顺利落地，其将正式开启「A+H」双资本平台驱动模式，未来有望持续领跑高端新能源赛道，书写行业发展新篇章。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亚太商訊) - 汽车产业迈向电动化、智能化转型的关键时刻，中国品牌正加速崛起。赛力斯集团股份有限公司（下称「赛力斯」，股份代号：9927）于10月27日正式开启港股招股，有望成为首家实现A+H两地上市的豪华新能源汽车企业。此次IPO，赛力斯计划全球发售100,200,000股股份，最高发售价为每股131.50港元，预计募集资金净额约129.249亿港元，并定于11月5日正式登陆香港联合交易所。此次上市由中金公司与中国银河国际担任联席保荐人。赛力斯旗下高端品牌「问界」（AITO）凭借其系列车型，已在30万元至50万元级别的细分市场中领跑，被业界誉为「中国的Mercedes Benz宝马」。问界以「智慧重塑豪华」为核心理念，不仅契合用户对智能科技与豪华驾乘的双重追求，同时也因其在辅助驾驶、智能安全及智能动力等方面的技术成果，被视为「中国的特斯拉」，展现出与全球顶尖智能电动车制造商一致的愿景。技术积淀与华为深度合作赛力斯的成功并非偶然，其背后是超过三十年的技术积淀。公司自1986年创立以来，深耕汽车制造领域，从传统燃油车的扎实制造基础，平稳过渡至新能源汽车的创新浪潮。2021年，问界品牌的发布标志着赛力斯正式锚定豪华新能源汽车赛道，并确立了「用户定义汽车」的市场导向与「软件定义汽车」的技术路线，迅速构筑起差异化的竞争优势。问界目前已形成M5、M7、M8、M9四大主力产品矩阵，通过精准的价格梯度与场景化功能组合，全面抢占高端用户市场。问界系列车型亦受益于与华为的深度合作，而华为作为智能汽车系统的领军者，为问界提供了强大的智能驾驶和智能座舱技术支持，使其在辅助驾驶的体验和智能化水平上，持续保持行业领先地位，这也是问界系列能够获得市场认可的关键要素。问界M9领跑高端市场问界品牌的强劲表现已在销售数据上得到充分印证。2024年，问界全年交付量达到38.71万辆，同比实现268%的爆炸性增长。在细分市场中，旗舰车型问界M9上市仅10个月内生产逾15万辆，一举拿下50万元级别的销量冠军宝座，展现出强大的品牌力和市场号召力。为保障产品质量与交付效率，赛力斯投入巨资建设「超级工厂」并优化数字化供应链体系，有力支撑了产品「上市即上量」的策略。在实现垂直上量交付的同时，问界M9系列在垂直上量交付中至今未出现任何重大质量问题，为业界树立了高质量交付的新标杆。赛力斯此次赴港上市，不仅是其发展历程中的重要里程碑，更将为国际投资者提供一个深度参与中国豪华智能电动车市场高速增长的绝佳机会。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) - OTS Holdings Limited (“OTS Holdings” or the “Company”, and together with its subsidiaries, the “Group”), a brand builder and food manufacturing group, is pleased to announce the grand opening of its new advanced food manufacturing facility located at Lot 1734, Jalan Kampung Pisang, Bukit Keremoiyang, 86200 Simpang Renggam, Johor Darul Takzim, Malaysia. The facility will operate under a wholly-owned subsidiary Ellaziq (Malaysia) Sdn. Bhd.The event on 28 October 2025 was graced by Yang Berhormat Tuan Lee Ting Han, Chairman of the Johor State Investment, Trade, Consumer Affairs and Human Resources Committee, along with representatives from the Malaysian Investment Development Authority (MIDA), Enterprise Singapore, the Singapore Business Federation, the Johor State Islamic Religious Department, as well as representatives from banking institutions, partners, and business associates.From left to right: 1. Mr. Mohamad Reduan Mohd Zabri, Director, MIDA Johor; 2. Ms. Wan Hariati Wan Salleh, Senior Deputy Director, Food Technology & Resources Based Industries Division, MIDA; 3. Yang Berhormat Tuan Lee Ting Han, Chairman of Johor State Investment, Trade, Consumer Affairs and Human Resources Committee; 4. Mr. Ong Bee Chip, Managing Director, OTS Holdings Limited; 5. Mdm. Ong Chew Yong, Executive Director, OTS Holdings Limited; and 6. Dr. Yu Lai Boon, Non-Executive Chairman and Independent Director, OTS Holdings LimitedWith a total investment of approximately RM40 million, the new Johor manufacturing facility is halal certified and equipped with new advanced F&B machinery and automation, boosting the Group’s monthly halal production capacity by up to 200 tonnes — more than three times of its Singapore’s halal production output.Backed by advanced production capabilities and in-house R&D expertise, the Group has undertaken extensive renovation and upgrading works, since acquiring the property for RM14.3 million in November 2023, to ensure the new facility aligns with the Group’s stringent food manufacturing standards, quality controls and operational requirements.With a land size of 178,863 square feet, the Johor manufacturing facility has a built-up area of 65,000 square feet that includes office space, production and maintenance facility with boilerhouse and workshop.Dedicated exclusively to halal production, the Johor manufacturing facility has successfully obtained its halal certification in August 2025.Notably, the Johor manufacturing facility is equipped with new advanced F&B machinery and automation, which will enable the Group to maintain stringent quality standards while operating with a lean workforce.In comparison to the Singapore facility, which produces 60 tonnes of halal products monthly within 17,000 square feet, the Johor plant will boast a capacity of up to 200 tonnes per month — more than three times of Singapore’s production output.Commenting on the grand opening of its new Johor manufacturing facility, Managing Director of OTS Holdings, Mr. Ong Bee Chip said: “Our new Johor facility reflects our commitment to meeting the evolving needs of the Muslim consumer segment, which continues to grow both in value and demand.Our focus is not just on increasing volume, but on creating products that resonate with the values and expectations of the Muslim community, while maintaining the stringent standards of food quality and safety.Targeting the growing Muslim consumer market locally and abroad—from Singapore and Malaysia to the Middle East, UAE, and Africa, our enhanced production capacity will also strengthen our export capabilities, extending our trusted halal brands and high quality products to a larger audience globally.”About OTS Holdings Limited(Bloomberg: OTS:SP / SGX Stock Code: OTS)Established in 1993, OTS Holdings Limited is a brand builder and food manufacturing group in the consumer industry with a strong niche in ready-to-eat and ready-to-cook meat products with key markets in Singapore and Malaysia.The Group’s vision is to develop a growing portfolio of established consumer brands and become an innovative market leader in the region. Targeting both halal and non-halal consumer segments, the Group has more than 1,100 SKUs across 13 main product types under its eight house brands and notably the Group’s flagship brands, “Golden Bridge” and “Kelly’s” have become established household names within the ready-to-eat and ready-to-cook meat products market in Singapore and Malaysia.The Group owns and operates three modern food manufacturing facilities, two in Singapore and one in Simpang Renggam, Johor, Malaysia. In Singapore, its integrated food manufacturing facilities with in-house research and development team span across around 98,285 square feet with an average annual production of around 2,500 tonnes of ready-to-eat and ready-to-cook meat products.The Group’s food products are sold in major supermarkets, convenience stores, provision shops, hotels and restaurants in Singapore and Malaysia. Having built an established sales and distribution network over the past few decades, the Group aims to expand its presence in existing markets and overseas.For more information, please visit the Company’s website at www.ots-holdings.com.Issued on behalf of OTS Holdings Limited by 8PR Asia Pte Ltd.Media & Investor Contacts:Mr. Alex TANMobile: +65 9451 5252Email: alex.tan@8prasia.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

LONDON, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) - New research from the Institute for Economics & Peace reveals that changing rainfall patterns are significantly amplifying conflict risks worldwide. The 2025 Ecological Threat Report (ETR), released today, finds conflict death rates are substantially higher in areas where rainfall is concentrating into fewer months, compared to regions where rain is spreading more evenly throughout the year.Ecological Threat Report 2025Analysing Ecological Threats, Resilience & PeaceKey FindingsOn average in areas where wet and dry seasons are becoming more extreme, there are four times as many conflict deaths as areas where it has decreased.In 2024, natural hazards triggered 45 million short-term internal displacements across 163 countries, the highest figure since at least 2008.Western Brazil, including parts of the Amazon, has recorded some of the world's sharpest increases in ecological threat levels. Temperatures have risen at twice the global rate, triggering drought and wildfires.Sub-Saharan Africa faces the world's most severe ecological pressures, with Niger registering the worst ETR score.Central and Western Europe recorded substantial overall improvements, in part representing a return to normalcy following Europe's unusually dry climatic conditions in 2019.Despite fears of looming water wars, there have been no interstate conflicts fought exclusively over water in the modern era. In the second half of the 20th century, at least 157 international freshwater treaties have been signed, offering models for interstate cooperation.This cooperative approach to water somewhat mirrors nuclear deterrence since the Second World War. In both cases, the very threat of catastrophic destruction has created pragmatic cooperation. The destruction of water supply can lead to societal collapse.Approximately 2 billion people - one quarter of humanity - now live in regions experiencing moderate to severe increases in seasonality. This is where wet seasons are becoming shorter and more intense, while dry seasons are longer and drier. These changes are disrupting agricultural calendars and heightening uncertainty for billions of people who rely on seasonal rains for food and livelihoods.The Ecological Threat Report, produced by the Institute for Economics & Peace, covers 3,125 sub-national areas in 172 countries and territories representing more than 99% of the world's population. Between 2019 and 2024, ETR scores deteriorated in 96 countries and improved in 74.Sub-Saharan Africa Approaching Multiple Critical Tipping PointsIn sub-Saharan Africa, conflict risk rises sharply when seasonality combines with rapid population growth. Unpredictable rains trigger agricultural stress. When coupled with demographic pressure, competition over land, water and food intensifies. In regions with weak governance and unresolved grievances, this combination proves combustible.The Karamoja Cluster in East Africa illustrates this pattern. While total rainfall remains relatively stable, its timing has become less predictable, amplifying both drought and flood hazards, leading to increased conflict. With only 2% of cultivated land irrigated compared to a global average of 20%, East African communities remain highly vulnerable to these shocks. Since 2019, increased rainfall seasonality has coincided with a resurgence of pastoralist violence after years of relative peace."Rainfall seasonality is becoming a powerful conflict catalyst,"said Steve Killelea AM, Founder & Executive Chairman of the Institute for Economics & Peace."Where rains are increasingly concentrated into fewer months, conflict deaths rise sharply. In sub-Saharan Africa, rapid population growth amplifies this effect, turning unpredictable seasons into competition for land, water and food. The issue isn't water scarcity - it's our failure to capture and distribute it. Only 2% of Sub-Saharan African farmland is irrigated, compared to 20% globally."Water Inequality and the Infrastructure GapThe world's renewable freshwater supply is finite and increasingly unevenly distributed. There are 295 subnational areas facing very high water risk and another 780 with high risk, affecting nearly 1.9 billion people.High-income countries have reduced per capita water use by roughly one-third since 2000 through efficiency gains and slower population growth, while many low-income nations face rising total withdrawals and falling per capita availability as populations outpace supply.Sub-Saharan Africa highlights this imbalance. Per capita water use has dropped from 113 cubic metres in 2000 to just 89 in 2022 - less than one-fifth of the global average. The result is mounting pressure on limited water sources and intensifying competition among farms, industries and households, heightening the risk of conflict.The failure to capture and distribute water is most acute in sub-Saharan Africa, which has the lowest irrigation rates in the world. To irrigate 34 million hectares would require only 6% of the region's annual renewable water resources.Steve Killelea said: "COP30 must prioritise investment in climate-resilient water systems as a foundation for sustainability and peace. Just as nuclear treaties reduced the risk of annihilation, international cooperation on water can reduce the risk of ecological collapse. Both demonstrate that survival depends less on dominance, than on shared responsibility."Interstate Water CooperationPopular narratives have warned of looming "water wars", especially in transboundary river and lake basins. The ETR finds this is not the case. While disputes over shared rivers do occur, no interstate wars have been fought over water in the modern era. This makes the lessons of successful interstate water cooperation even more important. In an era of increasing conflict, understanding why interstate cooperation has been so successful can provide a blueprint for avoiding future conflicts.Even in tense basins such as the Indus River - shared by India and Pakistan - water-sharing has continued despite repeated episodes of conflict, political confrontations and military tension. Water agreements, by necessity, encourage nations to think beyond immediate political grievances toward long-term survival and shared benefit.Regional AnalysisSub-Saharan Africa faces the world's most severe ecological pressures. However, some southern and eastern African countries, including Lesotho, Rwanda, Eritrea and Eswatini, have improved their ETR scores. More favourable rainfall patterns in these countries resulted in marked reductions in water risk over the past five years.In contrast, northwest Africa has seen the steepest deterioration in ETR scores over the same period, led by Tunisia, Morocco and Algeria, where persistent drought and rising temperatures have reversed the unusually favourable conditions of 2019.Central and Western Europe recorded notable improvements, marking a return to normal following the extreme dryness of 2019.Contact InformationMike KoslowskiIEP Senior Communications Advisormkoslowski@economicsandpeace.org+61418410531SOURCE: Institute for Economics & PeaceRelated Images Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月29日 - (亚太商訊) - 2025年10月28日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"，股票代码：1788.HK）作为联席保荐人、整体协调人、保荐人兼整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人，助力中国领先的企业级大模型人工智能应用解决方案提供商滴普科技股份有限公司（"滴普科技"，股票代码：1384.HK）于10月28日在香港联交所主板成功上市。滴普科技本次港股成功上市，是国泰海通集团充分整合境内外资源的又一典范之作。在本项目中，国泰君安国际充分发挥其沟通协调与执行能力，开展了精准高效的路演推介与深入的投资者沟通，成功助力本次IPO成为中国企业级大模型人工智能应用解决方案领域募资规模领先的港股项目，进一步巩固了滴普科技在企业级大模型人工智能解決方案市场的竞争优势。本次项目的成功执行，彰显了国泰君安国际在港股IPO市场，尤其是服务新经济及特专科技企业方面的领先地位。本次发行最终定价为每股26.66港元，总发售股数达2,663.2万股，总集资额约为7.1亿港元。香港公开发售录得踊跃认购，认购倍数约为7,569倍，显示出市场对滴普科技在企业级人工智能解决方案领域领先地位及未来增长潜力的高度认可。公司计划将募集资金用于以下战略方向：约40%用于提升研发能力；约30%用于扩大在中国的销售网络及客户群；约15%用于海外业务扩张；约5%用于潜在投资及并购；10%将作为营运资金及一般公司用途。此资金规划将为滴普科技巩固技术壁垒和加速商业化进程提供坚实动力。早在2021年，国泰君安国际联合领投滴普科技1亿美金B轮融资，2022年认缴完毕，充分展现了公司前瞻性地布局人工智能赛道、精准把握高成长企业潜力的战略眼光，也为后续助力滴普科技登陆港股市场奠定了坚实的合作基础。未来，国泰君安国际将继续凭借其专业的金融服务能力，致力于为更多创新科技企业连接全球资本市场。关于滴普科技滴普科技是中国领先的企业级大模型人工智能应用解决方案提供商，通过其FastData企业级数据智能解决方案和FastAGI企业级人工智能解决方案助力企业大规模高效整合数据、决策及运营。以2024年收入计，滴普科技在中国企业级大模型人工智能应用解决方案市场排名第五。其解决方案已实现多个垂直行业的规模商业化落地，覆盖消费零售、制造、医疗及交通等领域。截至2025年6月30日，滴普科技为各行业累计283名企业用户提供服务，复购客户占比33.2%，体现了高度的客户黏性及客户满意度。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球84%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) – October 28, As the joint sponsor, overall coordinator, sponsor-overall coordinator, joint global coordinator, joint bookrunner and joint lead manager, Guotai Junan International Holdings Limited (“GTJAI”, stock code: 1788.HK), a company of Guotai Haitong Group, facilitated the successful listing of Deepexi Technology Co., Ltd. (“Deepexi Technology”, stock code: 1384.HK), a leading enterprise large model AI application solution provider in China, on the main board of the Hong Kong Stock Exchange on October 28.The successful listing of Deepexi Technology exemplifies Guotai Haitong Group’s strength in integrating domestic and international resources. In this project, GTJAI fully leveraged its communication, coordination and execution capabilities to conduct precise and efficient roadshows and in-depth investor engagement. This successfully positioned the IPO as the leading Hong Kong-listed project in terms of fundraising scale of China's enterprise large model AI application solution sector, further solidifying Deepexi Technology’s competitive edge in the enterprise large model AI application solution market. The successful execution of this project underscores GTJAI’s leading position in the Hong Kong IPO market, particularly in serving new economy and specialized technology enterprises.The final offering price of this issuance is set at HK$26.66 per share, with a total of 26.632 million shares offered. The total funds raised amount to approximately HK$710 million. The Hong Kong public offering recorded an overwhelming subscription, with an oversubscription ratio of approximately 7,569 times, demonstrating the market's strong recognition of Deepexi Technology’s leading position in the enterprise large model AI application solution sector and its future growth potential. The company plans to allocate the raised funds to the following strategic directions: approximately 40% for enhancing R&D capabilities; approximately 30% for expansion of sales network and customer base in China; approximately 15% for overseas business expansion; approximately 5% for potential investment, mergers and acquisitions; and 10% for working capital and general corporate purposes. This funding plan will provide solid momentum for Deepexi Technology to consolidate its technological barriers and accelerate its commercialization process.Notably, as early as 2021, GTJAI co-led a USD$100 million Series B financing round for Deepexi Technology , which was completed in 2022. This early involvement demonstrated GTJAI’s strategic foresight in identifying high-growth potential in the AI sector and laid a solid foundation for subsequent collaboration in supporting Deepexi Technology’s listing in Hong Kong. In the future, GTJAI will continue to leverage its professional financial services capabilities to connect more innovative technology companies with global capital markets. About Deepexi TechnologyDeepexi Technology is China's leading provider of enterprise large model AI application solutions. Through its FastData enterprise data intelligence solution and FastAGI enterprise AI solution, it empowers enterprises to integrate their data, decisions and operations efficiently at scale. Deepexi Technology ranked fifth in China’s enterprise large model AI application solution market in terms of revenue in 2024. Its solutions have achieved large-scale commercialization across multiple verticals, including consumer goods, manufacturing, healthcare and transportation. As of June 30, 2025, Deepexi Technology served a cumulative total of 283 enterprise customers across various industries, with multiple engagements representing 33.2% of customer base, reflecting strong customer loyalty and satisfaction. About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月29日 - (亚太商訊) - 2025年10月28日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK）作为独家保荐人、保荐人兼整体协调人、整体协调人、联席全球协调人、联席账薄管理人及联席牵头经办人，成功助力上海剑桥科技股份有限公司（"剑桥科技"，股份代号：6166. HK，603083.SH）在香港联交所主板上市。剑桥科技由此成为光模块及CPO（Co-packagedoptics，光电共封装技术）领域首家实现"A+H"双平台上市的企业。此次港股发行创下A股与港股通信设备行业有史以来最大规模IPO纪录，充分彰显国泰海通集团在跨境资本运作中高效整合资源、服务大型科技企业的综合实力。本次发行最终定价为每股68.88港元，总发售股数达6,701万股，基础发行规模46.16亿港元，超额配售权完全行使后预计总集资额将达53.08亿港元。国际配售和香港公开发售录得踊跃认购，国际配售认购倍数达16.5倍，香港公开发售认购倍数达338.7倍。截至2025年10月28日，以募资规模计，本项目为2025年前三大独家保荐港股IPO项目。在项目执行过程中，国泰君安国际凭借高效的沟通协调与执行力，助力剑桥科技在六个月内完成从递交H股上市申请到成功在港挂牌的全流程。项目团队深入挖掘和打造公司投资故事，聚焦公司在AI基础设施、光通信及光模块领域的领先地位及技术优势，开展扎实深入的市场推介工作，对接全球顶尖投资者，帮助剑桥科技引入霸菱、摩根士丹利、HCEP、Arc Avenue、奇点资产、Weiss、Cithara、3W、Schonfeld、无极资本、Alpine、Dymon Asia、博裕、Martis、泰康人寿、工银理财共计16名顶尖基石投资者，基石投资占比48.89%，涵盖顶尖外资长线基金、知名外资多策略基金、中资长线基金，并于国际配售中进一步引入众多全球顶尖长线基金和主权基金订单，既展现了国泰君安国际领先的全球投资者覆盖能力，也凸显了全球顶尖资本对剑桥科技长期发展前景的信心。关于剑桥科技剑桥科技是全球领先的AI基础设施提供商，专注于光模块、宽带和无线等联接与传输设备的设计、研发、制造与销售，其产品广泛应用于算力集群内部、算力集群之间、算力集群与用户之间以及用户端内部大量算力和数据的高效连接，下游客户包括全球领先的人工智能数据中心、电信运营商、ICT设备提供商、多系统运营商及物联网解决方案提供商。公司在中国、美国及日本设立了六大研发中心，通过自有工厂和Co-location合作模式，公司在中国、美国、欧盟及马来西亚设立了七大生产基地。凭借公司在行业内的强势地位及广泛的全球布局，公司将持续受益于人工智能高速发展带来的巨大增长机遇。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球84%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) – October 28, As the sole sponsor, sponsor-overall coordinator, overall coordinator, joint global coordinator, joint bookrunner and joint lead manager, Guotai Junan International Holdings Limited (“GTJAI” or “the Company”, stock code: 1788.HK), a company of Guotai Haitong Group, facilitated the successful listing of CIG SHANGHAI CO., LTD. (“CIG”, stock code: 6166.HK，603083.SH) on the main board of the Hong Kong Stock Exchange. This listing establishes CIG as the first photonics and CPO (Co-packaged Optics) company with dual listings in both the A-share and H-share markets. Marking the largest IPO ever in the telecommunications equipment sector across these markets, the offering fully demonstrates Guotai Haitong Group's comprehensive capabilities in resource integration and serving large technology enterprises through cross-border capital operations. The final offering price for this issuance is set at HK$68.88 per share, with a total of 67.01 million shares offered, representing a base offering size of HK$4.616 billion. Upon full exercise of the over-allotment option, the total proceeds are expected to reach HK$5.308 billion. The offering attracted strong investor interest, with the international placement oversubscribed by approximately 16.5 times and the Hong Kong public offering oversubscribed by approximately 338.7 times. As of October 28, 2025, this transaction ranks among the top three Hong Kong IPO projects by fundraising size led by a sole sponsor in 2025. Throughout the project execution, GTJAI leveraged its efficient communication, coordination and execution capabilities to assist CIG in completing the entire process—from submitting its H-share listing application to successfully listing in Hong Kong—within six months.The project team conducted in-depth research and crafted the company's investment narrative, highlighting its leading position and technological advantages in AI infrastructure, optical communication and photonics. Through robust and thorough market outreach, they connected with the world's top investors and assisted CIG in engaging a total of 16 top-tier cornerstone investors, including Barings, Morgan Stanley, HCEP, Arc Avenue, CloudAlpha Capital, Weiss, Cithara, 3W, Schonfeld, Infini Capital, Alpine, Dymon Asia, Boyu, Martis, Taikang Life and ICBC WM with cornerstone investments accounting for 48.89% of the total. These investors encompass premier foreign long-term funds, renowned foreign multi-strategy funds and Chinese long-term funds. International placement further secured orders from numerous top global long-term funds and sovereign wealth funds. This achievement not only demonstrates GTJAI’s leading global investor coverage capabilities but also underscores the confidence of world-class capital in CIG’s long-term development prospects. About CIGCIG is a globally leading AI infrastructure provider specializing in the design, R&D, manufacturing and sales of connectivity and transmission equipment such as photonics, broadband and wireless solutions. Its products are extensively deployed for efficient connectivity within computing clusters, between clusters, between clusters and users, and within user endpoints to manage massive computing power and data flows. Its downstream clients include world-leading AI data centres, telecom operators, ICT equipment providers, multiple system operators and internet-of-things solutions providers. The company has established six major R&D centres in China, the United States and Japan. Through its own manufacturing facilities and Co-location partnerships, it has set up seven production bases in China, the United States, the European Union and Malaysia. Leveraging its strong industry position and extensive global footprint, the company will continue to benefit from the tremendous growth opportunities presented by the rapid advancement of artificial intelligence.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- 第20届国际环保博览今天起一连四天于亚洲国际博览馆举行，吸引来自13个国家及地区、约340家展商参与- 博览多元活动和产品科技响应施政报告，涵盖循环经济及废物处理、绿色及智慧出行、以及ESG相关服务三大领域- 大会将于明天举行「环保企业"走出去" 经验交流会」，多位一带一路国家政府官员及半官方机构代表分享开拓当地市场策略，助环保企业拓阔国际网络香港, 2025年10月28日 - (亚太商訊) - 由香港贸易发展局（香港贸发局）、法兰克福展览（香港）有限公司合办，并由香港特别行政区政府环境及生态局协办的第20届国际环保博览，今日起一连四天（10月28至31日）于亚洲国际博览馆举行，吸引来自13个国家及地区、约340家展商，带来各式创新环保科技产品、ESG及可持续发展方案，为业界打造优质的商贸平台。博览最后一天（即10月31日）为公众日，免费开放予公众人士入场，鼓励市民参与环保活动，实践绿色生活。中华人民共和国生态环境部副部长于会文、工业和信息化部节能与综合利用司副司长丁志军、香港特别行政区环境及生态局局长谢展寰、香港贸发局总裁张淑芬、法兰克福展览（香港）有限公司执行董事李庆新等，今日出席国际环保博览开幕典礼。香港贸发局总裁张淑芬表示：「今年国际环保博览迎来第20届的重要里程碑，不仅展示我们对可持续发展的承诺，也凸显我们持续推动绿色创新及与绿色业界合作生态圈的使命。今年博览以『绿色科技 引领零碳未来』为主题，为绿色产业提供宝贵的交流机会，再次匯聚业界领袖共同为永续的未来铺路，这亦与香港特区政府的净零排放目标互相配合。」环境及生态局局长谢展寰于开幕典礼致辞时表示：「在全球迈向可持续发展的过程中，香港发挥『超级联繫人』的角色。凭藉我们作为粤港澳大湾区内国际都会的独特地位，以及担当中国内地对接世界的桥樑，香港匯聚人才、科技与资本，能促进合作和扩大绿色创新。」环球展商云集 展示创新环保科技今年博览共有17个展团，本地方面，环境运动委员会首次组织展馆，带来22家本地绿色初创，还有环境及生态局等11个政府单位组成的展区等。中国内地包括广东、广州、深圳、广西、湖南、上海、内蒙古亦组团参展。由『一带一路』国际科学组织联盟(ANSO)及11家内地企业组成的ANSO环境科技产业联盟展馆更首次亮相，展示与水资源和大气环境有关的技术，藉着参展为联盟企业开拓海外市场奠定基础。海外展团方面，今年新增韩国及意大利展团，挪威、荷兰及加拿大展团亦载誉归来。大会积极建构平台协助港商及内地企业「出海」，吸引来自日本、泰国、印尼、马来西亚、新加坡、越南、匈牙利及波兰的买家组团参观及採购。至于明天举行的「环保企业"走出去"经验交流会」，特区政府邀请多位一带一路国家政府官员及半官方机构代表分享开拓当地市场策略。大会亦与环境及生态局合作，广邀内地、东盟及「一带一路」国家政府的服务供应商，亲临博览採购环保科技及产品。三大领域响应施政报告 智能与环保兼具环保成为近年政策焦点之一，中国内地近期发布《关于推进绿色低碳转型加强全国碳市场建设的意见》，成为指引「十五五」时期中国碳市场深化改革的纲领性文件。今年政府亦提出建设绿色低碳生活环境，致力加速绿色技术应用等。配合产业发展，博览匯聚多元绿色科技，展示循环经济及废物处理、绿色及智慧出行、以及ESG相关服务三大领域最新成果。在循环经济及废物处理展区，绿色人工智能科技（展位编号：3-D38）展示AI 智能分类垃圾桶，装置可透过即时AI废物识别，提供互动学习体验，教授正确回收方法。另外，绿色动力环保集团（展位编号：3-E30）带来再生能源发电厂项目，助力城市永续发展。于绿色及智慧出行领域，内地装备制造业龙头三一集团港澳地区子公司三一腾飞机械（展位编号：6-C26）则带来三一锂能电源车，可同时为两台电动卡车充电。 内地洁净能源设备制造商中集安瑞科控股有限公司（展位编号：3-F14），展示用于运输和储存氢能及绿色甲醇的创新技术方案。博览亦带来ESG相关服务，Llewellyn and Partners Company（展位编号：6-D14）带来为建筑业而设的专利AI 综合管理平台AutoTwin，协助减少建筑运营成本、时间及碳排放。加拿大科技公司XSIM AI Canada Inc.（展位编号：6-C23）则透过AI驱动的系统，为污水处理厂及工业设施减少高达30%的停机时间、营运成本及碳排放。学研机构与初创亦不容忽视，除香港中文大学（展位编号：3-G24）亦再度参与外，岭南大学（展位编号：6-A25）和香港理工大学晋江技术创新研究院（展位编号：6-A23）今年首次参展。香港科技园公司（展位编号：3-F20）带来初创afterNATURE（展位编号：3-F20），展出六角形深水盆，用以维持海岸线的生态与海洋生物多样性而设。另一家园区初创远见筑（展位编号：3-F20）则展示AtmosBrick 及于博览全球首发AtmosTile「负碳」绿建材，将二氧化碳转化为高性能建材，大幅降低碳足迹。业界领袖聚首「亚洲环保会议」建造业与交通运输业成焦点博览焦点活动「亚洲环保会议」今天举行政府环节，中华人民共和国工业和信息化部节能与综合利用司副司长丁志军在会上分享国家最新环保政策及动向，缅甸、斯里兰卡、菲律宾等多个一带一路国家的政府官员亦会讲解当地最新绿色政策及项目；同日另一环节则以「循环经济：革新与创新解决方案」为主题，由商界环保协会带领多位专家，探讨如何在商业运营上应用循环经济概念，会议中亦会首度推出《香港循环建筑环境指南》，为建造业带来最新绿色指引。博览第三日（10月30日）的会议主题围绕「构建可持续未来：迈向净零建筑环境」及「绿色智慧出行 - 引领未来出行潮流」，邀请多位业界领袖及专家分享真知灼见，包括机电工程署副署长陈柏祥、香港生产力促进局先进能源及智慧交通中心技术及商品化主管莫天德博士等，分别讨论建筑业及交通运输行业如何透过有效合作，构建可持续发展城市。其他精彩活动包括博览首日（10月28日）的「香港工业总会．Q唛低碳餐厅大奖」颁奖典礼；于第二日（10月29日）举行的第六届氢能经济论坛，香港特区政府环境及生态局副局长黄淑娴届时会带来主题演讲，而中国城市燃气氢能发展创新联盟副理事长王子缘将分享粤港澳大湾区氢能机遇与挑战。博览同时设有不同研讨会，包括为推动绿色初创企业发展而设的「初创．动起来」，邀请来自不同环保领域的初创代表进行分享。博览于最后一天（10月31日）为公众日，免费开放予市民入场，鼓励市民参与环保活动。当日特设一系列的环保生活讲座、工作坊和活动，当中包括近期热话极端天气，由香港天文台总学术主任陈敏仪进行分享；海洋公园亦会分享「逆濒行动 Mission R」保护濒危野生动物与其栖息环境的相关资讯。市民亦可参与不同环保工作坊，同场亦设有绿色市集供市民选购环保产品。其他同期活动香港国际户外及科技照明博览在10月28至31日同于亚博馆举行，展示各种商业和工业用的室外及专业技术照明解决方案，而香港国际秋季灯饰展（秋灯展）已于昨天起一连四天（10月27日至30日）在香港会议展览中心举行。大会已安排免费穿梭巴士服务，往来展场及各主要酒店与交通交匯点。详情请参阅以下网页︰https://www.hktdc.com/event/ecoexpoasia/sc/travel-to-fairground-awe图片下载：https://bit.ly/48MjH8F由香港贸发局及法兰克福展览（香港）有限公司合办的第20届国际环保博览揭幕，博览一连四天（10月28至31日）假亚洲国际博览馆举行，吸引约340家展商参与。图为中华人民共和国生态环境部副部长于会文、工业和信息化部节能与综合利用司副司长丁志军、香港特别行政区环境及生态局局长谢展寰、香港贸发局总裁张淑芬及一众嘉宾，出席国际环保博览开幕典礼盛况。中华人民共和国生态环境部副部长于会文（左三）、香港特别行政区环境及生态局局长谢展寰（右三）、香港贸发局总裁张淑芬（左二）及一众嘉宾到场参观。香港特区政府邀请多位一带一路国家及地区的政府官员及半官方机构代表出席第20届国际环保博览，包括柬埔寨、缅甸及斯里兰卡等。今年博览共有17个展团参展，当中包括环境运动委员会首次组织展馆，带来22家本地初创。海外展团方面，今年新增韩国展团，阵容鼎盛。绿色及智慧出行属今年新增领域，聚焦于各种崭新的绿色运输方案及产品。业界新血亦不容忽视，学研机构与初创带来创新绿色方案。「亚洲环保会议」邀请来自世界各地的官员、行业领袖和专家，就不同议题分享真知灼见。网页国际环保博览：www.ecoexpoasia.com/sc传媒查询请联络香港贸发局传讯及公共事务部：苏显博电话：(852) 2584 4049电邮：stanley.hp.so@hktdc.org刘茸电话：(852) 2584 4472电邮：clayton.y.lauw@hktdc.org香港贸发局新闻中心︰http://mediaroom.hktdc.com/sc香港贸易发展局简介香港贸易发展局(香港贸发局)是于1966年成立的法定机构，负责促进、协助和发展香港贸易。香港贸发局在世界各地设有超过50个办事处，其中13个设于中国内地，致力推广本港作为双向环球投资及商业枢纽。 香港贸发局通过举办国际展览会、会议及商贸考察团，为企业(尤其是中小企业)开拓内地和环球市场的机遇。香港贸发局亦通过研究报告和数码资讯平台，提供最新的市场分析和产品资讯。有关香港贸发局的其他资讯，请浏览www.hktdc.com/aboutus/tc。法兰克福展览集团简介法兰克福展览集团是全球最大的拥有自主展览场地的展会主办机构之一，其业务覆盖展览会、会议及活动，在全球29个地区聘用约2,160名员工，业务版图遍及世界各地。2022年营业额约4.54亿欧元，集团与众多行业领域建立了丰富的全球商贸网络并保持紧密联繫，在展览活动、场地和服务业务领域，高效满足客户的商业利益和全方位需求。法兰克福展览集团核心优势在于遍布世界各地庞大、紧密的国际行销网络，覆盖全球约180个国家。多元化的服务呈现在活动现场及网络平台的各个环节，确保遍布世界各地的客户在策划、组织及进行活动时，能持续享受到高品质及灵活性。我们正在通过新的商业模式积极拓展数字化服务范畴，可提供的服务类型包括租用展览场地、展会搭建、市场推广、人力安排以及餐饮供应。作为核心战略体系之一，集团积极实践可持续化经营理念，在生态、经济利益、社会责任和多样性之间达成有益的平衡。有关集团可持续发展进一步资料，请浏览网页：www.messefrankfurt.com/sustainability。集团总部位于德国法兰克福市，由该市和黑森州政府分别控股60%和40%。有关公司进一步资料，请浏览网页：www.messefrankfurt.com.hk。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com